Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430040 · ClinicalTrials.gov registry record · Phase 4
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.
A Phase 4 study, sponsored by University at Buffalo.
- Terminated
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT00430040: Clinical Trial Phase 4 study, sponsored by University at Buffalo.
NCT00430040 is a Phase 4 study that was terminated before completion, run by University at Buffalo. The registered enrollment target is 14 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00430040, a Phase 4 study, was terminated before completion, sponsored by University at Buffalo.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
To determine whether addition of Carvedilol CR to diabetic patients with hypertension who are receiving the ACEi,Lisinopril,will provide added benefits to blood vessels when compared to treatment with Lisinopril alone.It is believed that carvedilol provides added benefits by suppressing free radicals(charged substances that cause damage to the body ) and inflammation.
Primary Outcome
Percent change from baseline in Brachial artery vascular reactivity at 6 months calculated as: (brachial reactivity at 6 months-brachial reactivity at 0 months)/brachial reactivity at 0 month \*100
Interventions
- DRUG lisinopril
- DRUG Carvedilol Controlled Release (CR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-02 |
| Est. Completion | 2013-05 |
| Phase | Phase 4 |
Why NCT00430040 stopped before completion
NCT00430040 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which lisinopril is the first listed.
NCT00430040 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00430040 about?
NCT00430040 is a clinical study titled "Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.". To determine whether addition of Carvedilol CR to diabetic patients with hypertension who are receiving the ACEi,Lisinopril,will provide added benefits to blood vessels when compared to treatment with Lisinopril alone.It is believed that carvedilol provides added benefits by suppressing free radical...
What is the current status of trial NCT00430040?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2007-02. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00430040?
The interventions under investigation include: lisinopril (DRUG), Carvedilol Controlled Release (CR) (DRUG).
Who is sponsoring clinical trial NCT00430040?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00430040's enrollment target sits among peer trials
14 1901st of 2000 higher than 91 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia